Corbett Accel taps Cooper-Broski as new EVP,CMO

Share this article:

Omnicomm unit Corbett Accel Healthcare Group has hired 30-year advertising veteran Elisa Cooper-Broski, to serve as its new EVP and chief marketing officer (CMO).

In her new role, Cooper-Broski will direct Corbett Accel's business development strategy and lead brand-building efforts for the company's five business units in conjunction with the business unit leaders.

Cooper-Broski will be based in Corbett Accel's New York office and will report directly to CEO Scott Cotherman.

“The CMO role is relatively unknown in pharmaceutical advertising,” said Cotherman. "We are one of the first to identify the value a chief marketing officer brings to an organization. Elisa Cooper-Broski's extensive knowledge of the pharmaceutical industry, along with her multi-faceted experience, will be invaluable as we advance our integrated business development strategy."

Cooper-Broski previous experience includes work with GSW New York's presence, Saatchi & Saatchi Healthcare (formerly Klemtner Advertising) CommonHealth USA and NCI Advertising (formerly Rolf Werner Rosenthal).

Prior to joining Corbett Accel, Cooper-Broski was president and chief branding officer for Bruce Leeb & Company, a privately held healthcare advertising agency.

“In this environment, my role as CMO will strengthen the overall impact of Corbett Accel and its business units in the pharmaceutical industry as a communications company that delivers visionary results with substantial and beneficial outcomes” said Cooper-Broski in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.